Novo and Pivotal BioVenture Partners both invested as the lung disease therapy developer took its overall funding close to $100m.
Month: April 2020
Velo3D adds $28m in series D funding
The metal printing technology producer increased its total funding to $138m in a round led by Petronas-sponsored Piva that included TNSC.
Federated Wireless extends series C round
The mobile frequency technology provider added $13.7m to an SBA Communications and American Tower-backed round now sized at $64.7m.
Actym Therapeutics actions $34m series A
Boehringer Ingelheim Venture Fund co-led the cancer immunotherapy developer’s series A round, which also featured Illumina Ventures.
Corporates help cover Qoala’s series A
The online insurance provider received $13.5m in a round led by Centauri Fund and backed by MassMutual Ventures, MDI Ventures and Central Capital Ventura.
Cai comes over to Vision Fund
Daisy Cai has returned to corpoorate venturing two years after leaving Baidu, joining SoftBank Vision Fund as its newest partner.
Starbucks drinks to China partnership
The blurring of lines between corporate and independent venture capital is continuing apace as all parties consider how best they can support entrepreneurs while fulfilling their five needs: capital, customers, product development, hiring and an exit.
Google delves into D2iQ acquisition options
The potential acquisition would reportedly value the HPE, Microsoft and Koch-backed cloud software provider below its most recent valuation but above $250m.
LifeSprout bolts on series A funding
Medytox-backed restorative materials technology developer Lifesprout secured $28.5m in a round led by Redmile Group as it looks to move into regenerative medicine.
Cross River cracks $100m series C
The CreditEase-backed banking services provider is targeting a 2021 initial public offering following a round co-led by V Capital and Shefa Capital.
Compass points to $80m series B
Otsuka Pharmaceuticals’s McQuade Center for Strategic Research and Development backed the psilocybin-based mental health drug developer through the round.
Corporates head to Rome for $50m series A
Repeatome drug developer Rome Therapeutics was incubated within GV, which took part in the series A round along with fellow corporate unit Partners Innovation Fund.
Brain Corp sweeps up $36m
The robotics AI technology developer pulled in $36m through a series D round led by SoftBank Vision Fund that included fellow existing investor Qualcomm Ventures.
Starbucks and Sequoia brew Chinese investment pact
The coffee chain has selected Sequoia Capital China as its partner for a strategic investment campaign in one of its two largest growth markets.